Kanazawa University Research: Kanazawa University Invites Industry Collaboration for Cutting-Edge Bio-SPM Research
KANAZAWA, Japan, March 3, 2025 /PRNewswire/ -- Kanazawa University's Nano Life Science Institute (WPI-NanoLSI) is now accepting proposals from industry partners for collaborative research utilizing the world's most advanced bio-scanning probe microscope (Bio-SPM) technology. This initiative aims to foster groundbreaking industrial applications by leveraging WPI-NanoLSI's pioneering expertise in nano-life sciences.Advancing Industry Innovation with Bio-SPM TechnologyWPI-NanoLSI is dedicated to driving progress in nano-life sciences by advancing Bio-SPM technologies, including atomic resolution and 3D-AFM, high-speed AFM, scanning ion conductance microscopy (SICM), and cell measurement AFM. These techniques enable unprecedented visualization of dynamic biological and material phenomena at the nanoscale.Through this collaboration, industry researchers and engineers will have the opportunity to work alongside WPI-NanoLSI experts to explore innovative applications of Bio-SPM technology. The scope of research extends beyond biological samples, encompassing a wide range of materials and industrial applications. The advanced imaging capabilities of Bio-SPM offer the potential to capture nanometer-scale phenomena in motion—achievements that remain unattainable with conventional measurement techniques.
Why Partner with WPI-NanoLSI?With over 80 leading researchers and access to approximately 60 state-of-the-art Bio-SPM devices, WPI-NanoLSI has delivered significant scientific breakthroughs, including:- Structural analysis of microtubule interiors (Nano Lett., 2025) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/32417/
- Real-time visualization of glutamate receptor molecule dynamics (ACS Nano, 2024) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/31557/
- Observation of influenza virus genome synthesis processes (ACS Nano, 2024) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/31433/
- Study of intrinsically disordered protein structures (Nat. Nanotechnology, 2020) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/19908/
- Live-cell nanoscale imaging (Sci Adv, 2021) – https://nanolsi.kanazawa-u.ac.jp/en/highlights/22249/
For more details on the types of Bio-SPM and their applications, please visit the below link and click 'Overview of each Bio-SPM technology.'https://nanolsi.kanazawa-u.ac.jp/en/research/applications/bio-spm/
Application and Selection ProcessInterested companies can apply for collaborative research by specifying a WPI-NanoLSI researcher of choice or requesting assistance in finding a suitable research partner. Proposals will be evaluated based on their alignment with WPI-NanoLSI's Bio-SPM capabilities and the potential for impactful scientific and industrial advancements.Due to high demand, some applications may not be accepted despite meeting eligibility criteria.For more details on the application process, please visit the below link and click 'Application Guideline (for companies).'https://nanolsi.kanazawa-u.ac.jp/en/research/applications/bio-spm/
ContactResearch Collaboration Office,
WPI-NanoLSI, Kanazawa UniversityEmail : nanolsi_openf01@ml.kanazawa-u.ac.jp
About Kanazawa University and WPI-NanoLSIKanazawa University is a leading research institution dedicated to advancing science and technology on a global scale. The Nano Life Science Institute (WPI-NanoLSI) is at the forefront of nano-life science research, pioneering Bio-SPM technologies to explore biological structures and interactions with unprecedented detail.
Photo: https://mma.prnewswire.com/media/2631664/Kanazawa_University_BioSPMResearch.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/kanazawa-university-research-kanazawa-university-invites-industry-collaboration-for-cutting-edge-bio-spm-research-302389920.html
SOURCE Kanazawa University
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 days ago
- Associated Press
Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management
PITTSBURGH, June 26, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a landmark systematic review by researchers at Trinity College Dublin and the Royal College of Surgeons in Ireland (RCSI). Titled 'The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds', this review is the first to systematically compile data from 17 studies on fluorescence imaging.1 It conclusively establishes the crucial role of MolecuLight's technology in enhancing wound assessment by equipping clinicians with real-time, actionable information to effectively detect elevated bacterial burden, fundamentally transforming wound management. 'This new publication is a crucial step forward for MolecuLight. It provides a comprehensive review of existing evidence, further underscoring the essential role of MolecuLight's fluorescence imaging in elevating wound care,' said Anil Amlani, CEO of MolecuLight. 'Bacterial bioburden leads to infections and is a critical factor inhibiting wound healing, and this paper clearly articulates how our technology empowers clinicians to not only identify the presence and location of bacteria but also to guide targeted interventions. Ultimately, this leads to faster and more effective healing for patients, further strengthening the growing body of evidence supporting our technology's profound impact.' 'As a co-author of this systematic review and an academic and researcher who utilized MolecuLight's technology in practice, I can attest to the profound impact it has on clinicians' ability to manage complex wounds,' said study author Rosemarie Derwin, PhD, MSc, PG Dip, BNS, RGN, RNT, experienced nurse, educator, and researcher at the School of Nursing and Midwifery, Trinity College Dublin. 'The real-time visualization of bacteria provides immediate practical information that guides treatment decisions, leading to more effective care plans and ultimately, better outcomes for patients. This study affirms what many of us have seen clinically: MolecuLight is a vital asset in modern wound care.' This detailed systematic review of current evidence underscores the capability of MolecuLight devices to identify clinically significant levels of bioburden. This bioburden, frequently undetectable via visual inspection and present in over 80% of chronic wounds,2 frequently causes infection and necessitates targeted intervention. By visualizing bacterial fluorescence, clinicians are equipped to: MolecuLight continues to build on a robust foundation of clinical evidence. With over 100 peer-reviewed publications demonstrating the utility and impact of its fluorescence imaging technology, this systematic review powerfully reinforces that managing bacterial burden is essential for effective wound care. It affirms that MolecuLight devices provide an invaluable and proven tool for clinicians to achieve this, by enabling more precise and targeted interventions that hold strong promise for improved healing trajectories and enhanced patient quality of life. The company remains dedicated to advancing wound care through innovative solutions that improve patient lives and reduce healthcare costs. About MolecuLight Corp. MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only Class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. View original content to download multimedia: SOURCE MolecuLight
Yahoo
4 days ago
- Yahoo
Asteroid Day Gains Momentum with U.S. Recognition from Flagstaff, Coconino County, U.S. Senate, and Vera C. Rubin Observatory Data Release
LUXEMBOURG, June 25, 2025 /PRNewswire/ -- The Asteroid Foundation, working in collaboration with B612 Foundation, founding sponsor of Asteroid Day, is proud to announce significant advancements in the global recognition of June 30th as Asteroid Day. Following the United Nations' historic designation of the date as International Asteroid Day in 2016, local and national governments in the United States are now joining in to formally recognize this important awareness initiative. Since its inception, hundreds of independently organized Asteroid Day events have been taking place globally, calling attention to the critical need for awareness of both the dangers and possibilities associated with asteroids. This year, the movement celebrates official recognition from Flagstaff, Arizona, Coconino County, Arizona, and the United States Senate, marking a pivotal moment in bringing asteroid awareness to the forefront of public consciousness in the USA. Notably, these local, city, and national recognitions are the first in the world to highlight the profound importance of Asteroid Day in inspiring the next generation through Science, Technology, Engineering, Arts, and Mathematics (STEAM) activities. "As a retired astronaut, I know firsthand the importance of space research. Asteroid Day is a critical initiative that not only raises awareness about planetary defense but also ignites curiosity and inspires the next generation of scientists, engineers, and explorers to pursue careers in STEAM. I'm proud to introduce a resolution recognizing Asteroid Day in the United States Senate," said retired astronaut and U.S. Senator Mark Kelly (D-AZ). The Senate resolution was introduced in partnership with U.S. Senator John Cornyn (R-TX). "B612 Foundation, as the founding sponsor of Asteroid Day and a leading voice in asteroid analysis and mapping and planetary defense, championed the development of the 100x Declaration, a call to action that launched the global Asteroid Day movement. 'We are humbled and excited to see that in addition to the United Nations recognizing Asteroid Day on 6 December 2016, both Arizona and the United States government are now following suit,' said Danica Remy, Asteroid Day Co-founder and President of B612. 'I am additionally delighted that the US National Science Foundation and Department of Energy Vera Rubin Observatory is using Asteroid Day to release its first data product for scientists and the public. This growing momentum highlights the critical importance of understanding asteroid risks and opportunities for humanity's future." "This global movement would not have been possible without the visionary leadership of the Government of Luxembourg, particularly the contributions of former Deputy Prime Minister Etienne Schneider, today's CEO of Luxembourg's state innovation agency Luxinnovation Mario Grotz, and today's CEO of Luxembourg Space Agency (LSA) Marc Serres. Their efforts, alongside former NASA Ames Director Pete Worden and former Consul General and Executive Director Luxembourg Trade & Investment San Francisco Georges Schmit, as well as the dedicated leadership of the Asteroid Foundation board of directors, have amplified the Asteroid Day program globally," said Markus Payer, Chair of Asteroid Foundation. "The Luxembourg government's invitation to Asteroid Day co-founders, Apollo 9 astronaut Rusty Schweickart, Danica Remy, Grig Richters and Dr. Brian May, to establish the Asteroid Foundation in Luxembourg in 2017 provided the essential groundwork. This commitment was further solidified by the ongoing leadership of the LSA, which has played an instrumental role in supporting Asteroid Day's global program, alongside Luxembourg's rich local and cross-European in-person year-round initiatives." Asteroid Day serves as a global platform to educate the public about the exciting prospects of asteroid resource utilization and their role in understanding the origins of our universe, while also covering the role of asteroids in our solar system and the science and technology being developed to detect, track, and ultimately mitigate potential threats. About Asteroid Foundation: A Luxembourg based nonprofit, founded 2017, is the home of Asteroid Day and is dedicated to promoting public awareness and education about asteroids and space. Through global events, educational initiatives, and strategic partnerships, the Foundation strives to inspire a greater understanding of asteroids and their significance to our planet and humanity's future in space. For more information, visit or follow on social: Facebook, LinkedIn or Instagram. About B612 Foundation: A United States based nonprofit, founded in 2002, develops tools and technologies to understand, map, and navigate our solar system and protect our planet from asteroid impacts through its Asteroid Institute program and supporting educational programs, including Asteroid Day and the Schweickart Prize. Founding Circle and Asteroid Circle members and individual donors from 46 countries support the work financially. For more information, visit or follow on social: Twitter, Facebook, Linkedin or Bluesky. View original content: SOURCE Asteroid Foundation
Forbes
4 days ago
- Forbes
Ben Lamm Represents The Potential Of Biotech, And Why We Should Keep Supporting Innovators
The rapid adoption of artificial intelligence in genetic engineering, health care, and medical research could lead to significant improvements in human health and our ecological environment in the decades ahead. But biotech innovators and entrepreneurs worldwide will have to overcome a global political environment that has suddenly become skeptical of science, expertise and public health in general. Last week, 20,000 scientists, executives, investors and startups descended upon Boston for the BIO 2025 Convention – the largest medical research and biotech convening in the world. The convening took place amidst significant opportunity – and turmoil, in health care worldwide. The rapidly expanding capabilities of artificial intelligence are unlocking new opportunities to develop new drugs, therapeutics, wearables and devices. But BIO also comes at a time of significant declines in government funding for basic science and R&D, as well as a drop in global leadership around public health challenges like pandemic preparedness. BIO 2025 Exhibition Hall In 2025, the United States is expected to announce cuts of 40-60% to the National Institutes of Health and National Science Foundation. Yet American states are offering biotech's R&D credits, seed funding, lab space and commitments to improve their workforce and academic institutions. Nations around the world, sensing opportunity, are also rolling out the red carpet to attract the top scientists in the world. BIO itself highlighted the importance of building public trust in biotechnology and working with regulatory bodies to streamline approvals for innovative products. Colossal Biosciences is a great example of a biotech startup at the intersection of these trends and challenges. Founded by legendary geneticist Dr. George Church of Harvard and MIT, and serial AI entrepreneur Ben Lamm, Colossal is pioneering the use of CRISPR technology in the de-extinction of previously lost species, including the Dire wolf. According to the International Union for the Conservation of Nature, nearly 50% of all animal species could be endangered of becoming extinct by 2050. According to Lamm, 'We are the back-up plan. It's like, when we jump out of a plane, we all hope the parachute is going to open, but just in case, we want to have a back-up emergency 'chute. Colossal is that back-up.' The company defines de-extinction as the process of generating an organism that both resembles and is genetically similar to an extinct species by resurrecting its lost lineage of core genes; engineering natural resistances; and enhancing adaptability that will allow it to thrive in today's environment of climate change, dwindling resources, disease and human interference. The Dire Wolf, as imagined by Colossal Biosciences Such ambition and optimism were pervasive across BIO. Scores of startups today are using artificial intelligence for health care delivery, hospital operations, digital health platforms, diagnostics, patient monitoring tools, revenue cycle management, and even regulatory and compliance innovations. Biotech startups are using AI to improve drug discovery, target validation and optimize clinical trials. CRISPR, the ubiquitous gene editing tool now used in drug discovery, continues to improve as more genomes are mapped. Colossal has developed a set of new software tools and technologies, along with CRISPR gene editing technology to resurrect these specific species but to also build a 'de-extinction toolkit' that can be used for difference animal species as needed. According to Chief Science Officer, Dr. Beth Shapiro, a world-renowned evolutionary molecular biologist and a leading figure in the field of ancient DNA and paleo genomics, 'we are developing a modular system that combines gene editing, cryopreservation, synthetic biology, and cloning to preserve, restore, and recreate species.' As an example, the team at Colossal uses the genetics of the used the genetics of the closet relative of the team successfully used comparative genetics with its closest living relatives, the gray wolf, to fill in critical gaps in the genetic sequence. That cloning research that came from the project has immediate impacts on red wolf conservation and will serve as a critical tool for all canid restoration in the future. The biotech industry worldwide continues to grow in importance, and no doubt there will be continued investment in the basic science, R&D and commercialization that drives important companies like Colossal and others. It is less clear whether that leadership will come from the United States or other nations – such as the United Arab Emirates, India, China, Japan or elsewhere? We don't know what areas of innovation those nations will prioritize, and whether or not important moonshots – like bringing back the woolly mammoth, will be on their radar. American leadership – scientific, political and financial, needs to remain committed to improving health of humans and the planet at large.
